Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the French Society of Dermatology
Open Access
- 5 December 2020
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (5) , 963-965
Abstract
Hidradenitis suppurativa (HS) is a painful chronic inflammatory skin disease which impacts quality of life substantially. Its prevalence is estimated to 0.7%.1 Various pathophysiological hypotheses exist, but no therapeutic consensus, making the management of HS patients complex.Keywords
Funding Information
- Société Française de Dermatologie et de Pathologie Sexuellement Transmissible
This publication has 6 references indexed in Scilit:
- Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativaBritish Journal of Dermatology, 2018
- Oral ofloxacin and clindamycin as an alternative to the classic rifampicin–clindamycin in hidradenitis suppurativa: retrospective analysis of 65 patientsBritish Journal of Dermatology, 2017
- Development of resistance to Mycobacterium tuberculosis is manageable in hidradenitis suppurativa. Response to ‘Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis?’British Journal of Dermatology, 2017
- Mechanisms of Increased Resistance to Chlorhexidine and Cross-Resistance to Colistin following Exposure of Klebsiella pneumoniae Clinical Isolates to ChlorhexidineAntimicrobial Agents and Chemotherapy, 2017
- Microbial Profile and Antimicrobial Susceptibility of Bacteria Found in Inflammatory Hidradenitis Suppurativa LesionsSkin Pharmacology and Physiology, 2016
- Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combinationEuropean Journal Of Dermatology, 2014